Clinical trials: Lymphoid Hematological Malignancies
Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma
506U78 in Treating Patients With Refractory Hematologic Cancer
Phase II trial to study the effectiveness of 506U78 in treating patients with recurrent or refractory hematologic cancer. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die.
- Conditions
- Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Childhood Acute Lymphoblastic Leukemia
- Trial name
- NCT00002970
- Testing
- nelarabine, methotrexate, cytarabine
- Where
- United States
- Volunteers
- 148 people
- Sponsor
- National Cancer Institute (NCI)
Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm
Financial Navigation Program to Improve Understanding and Management of Financial Aspects of Cancer Care for Patients and Their Spouses
This clinical trial examines a financial navigation program in helping patients (and their spouses or partner caregivers, if participating) understand and better manage the financial aspects of cancer care.
- Conditions
- Hematopoietic and Lymphoid Cell Neoplasm, Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm
- Trial name
- CREDIT (NCT04960787)
- Testing
- Educational Intervention, Patient Navigation, Quality-of-Life Assessment
- Where
- 266 sites in United States, Puerto Rico
- Volunteers
- 331 people, healthy volunteers welcome
- Sponsor
- SWOG Cancer Research Network
Hematopoietic and Lymphoid Cell Neoplasm
Outcomes After Chimeric Antigen Receptor Therapy and Radiation Therapy for Hematologic Malignancies
This study collects information on outcomes after chimeric antigen receptor therapy and radiation therapy for hematologic malignancies.
- Trial name
- NCT04888338
- Testing
- Data Capture, Electronic Medical Record
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- M.D. Anderson Cancer Center
Chronic Myeloid Leukemia (CML), Pancreatic Ca
Natural Killer Cells and Bortezomib to Treat Cancer
Natural killer (NK) cells are white blood cells that have a limited ability to kill cancer cells. This ability might be enhanced if they are given 24 hours after an injection of the drug bortezomib.
- Conditions
- Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma
- Trial name
- NCT00720785
- Testing
- Bortezomib, NK cells
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Acute Leukemia in Remission, Myelodysplastic Syndromes
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
The aim of this study is to assess the Fecal Microbiota Transplantation (FMT) efficacy in the prevention of allogeneic hematopoietic stem cell transplantation (allo-HSCT) complications and particularly Graft versus Host Disease…
- Conditions
- Acute Leukemia in Remission, Myelodysplastic Syndromes, Myeloproliferative Syndrome, Hodgkin Lymphoma
- Trial name
- TMF-Allo (NCT04935684)
- Testing
- Fecal Microbiota Transplantation
- Where
- 20 sites in France
- Volunteers
- 150 people
- Sponsor
- University Hospital, Clermont-Ferrand
Advanced Lymphoma, Advanced Malignant Solid Neoplasm
Testing GSK2636771 as a Potential Targeted Treatment in Cancers With PTEN Genetic Changes (MATCH-Subprotocol N)
This phase II MATCH treatment trial identifies the effects of GSK2636771 in patients whose cancer has a genetic change called PTEN mutation or deletion.
- Conditions
- Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Refractory Lymphoma
- Trial name
- NCT04439149
- Testing
- PI3K-beta Inhibitor GSK2636771
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Combination Chemotherapy Plus Infusion of White Blood Cells in Treating Patients With Hematologic Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more cancer cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00003243
- Testing
- aldesleukin, filgrastim, therapeutic allogeneic lymphocytes
- Where
- United States
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Myeloid Leukemia, Lymphoblastic Leukemia
Efficacy and Safety of a Donor Lymphocyte Preparation Depleted of Functional Host Alloreactive T-cells (ATIR) in Patients Undergoing a Peripheral Blood Stem Cell Transplant From a Related, Haploidentical Donor
The purpose of this study is to determine whether the administration of a donor lymphocyte preparation depleted of functional host alloreactive T-cells (ATIR) after a T-cell depleted stem cell transplant from a related…
- Conditions
- Myeloid Leukemia, Lymphoblastic Leukemia, Lymphoma, Multiple Myeloma
- Trial name
- NCT00967343
- Testing
- Donor lymphocyte preparation depleted of host functional alloreactive T-cells
- Where
- 15 sites in United States, Belgium and 5 more
- Volunteers
- 40 people
- Sponsor
- Kiadis Pharma
Relapsed/Refractory, High Risk Hematologic Malignancies, T-ALL/Lymphoma
CD7 CAR-T Cell Treatment of Relapsed/Refractory CD7+ T -Acute Lymphoblastic Leukemia/ Lymphoma
This is a phase I, interventional, single arm, open label, treatment study to evaluate the safety and tolerability of CD7 CAR-T cells in patients with relapsed and/or refractory, high risk hematologic malignancies.
- Trial name
- NCT05212584
- Testing
- CD7CAR T cells
- Where
- China
- Volunteers
- 24 people
- Sponsor
- iCell Gene Therapeutics
Hematologic Malignancies
Safety of Romiplostim (Nplate®) Following UCBT
This is a single institution, phase I dose escalation study of weekly romiplostim post umbilical cord blood transplantation in patients who fail to achieve platelet engraftment by day +30.
- Trial name
- NCT02046291
- Testing
- Romiplostim
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Masonic Cancer Center, University of Minnesota
Hematologic Cancer
An Open Label Navigational Investigation of Molecular Profile-Related Evidence Determining Individualized Cancer Therapy for Patients With Incurable Hematologic Malignancies (I-PREDICT Heme)
The purpose of this study is to perform a prospective study that is histology-independent personalized navigation approach to cancer therapy based upon tumor molecular profile as determined by Clinical Laboratory Improvement…
- Trial name
- I-PREDICT Heme (NCT03955276)
- Testing
- Molecularly targeted treatment matched to genomic/immunophenotypic tumor profile (chosen by treating physician)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of California, San Diego
Lymphoma, Multiple Myeloma
Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY
The purpose of this research is to find the most effective and least toxic way to prevent GVHD after BMT.
- Conditions
- Lymphoma, Multiple Myeloma, Leukemia, Myelodysplastic Syndrome
- Trial name
- NCT00809276
- Testing
- Busulfan, Fludarabine, Cytoxan
- Where
- 3 sites in United States
- Volunteers
- 92 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Hematopoietic and Lymphoid Cell Neoplasm, Malignant Solid Neoplasm
New Magnetic Resonance Imaging and Spectroscopy Software in the Improvement of Image Quality
This trial studies how well new magnetic resonance imaging (MRI) and magnetic resonance spectroscopic imaging (MRSI) software works in improving the image quality of scans in both patients and healthy volunteers.
- Trial name
- NCT03980535
- Testing
- Magnetic Resonance Imaging, Magnetic Resonance Spectroscopic Imaging
- Where
- United States
- Volunteers
- 273 people, healthy volunteers welcome
- Sponsor
- M.D. Anderson Cancer Center
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML)
Haploidentical Stem Cell Transplant for Treatment Refractory Hematological Malignancies
Relapsed disease is the most common cause of death in children with hematological malignancies. Patients who fail high-intensity conventional chemotherapeutic regimens or relapse after stem cell transplantation have a poor…
- Conditions
- Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Secondary AML, Myelodysplastic Syndrome (MDS)
- Trial name
- NCT00145613
- Testing
- Stem Cell Transplantation, Miltenyi Biotec CliniMACS, Systemic chemotherapy and antibodies
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- St. Jude Children's Research Hospital
Graft vs Host Disease, Hematologic Neoplasm
Bone Marrow Transplant Studies for Safe and Effective Treatment of Leukemia
Bone marrow transplants (BMT) are one of the accepted therapies used to treat leukemia. However, BMT have risks of complications. One potentially life-threatening complication is known as graft-versus-host disease (GVHD).
- Conditions
- Graft vs Host Disease, Hematologic Neoplasm, Leukemia, Multiple Myeloma
- Trial name
- NCT00001623
- Testing
- Allogeneic Bone Marrow Transplant
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia
Occupational Status and Hematological Disease
Diseases do not only have a physical role in people's live, but they usually involve changes in life as whole. They may modify the structure of the conjunction with life setting, thus, deeply impacting relationships with others.
- Conditions
- Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myelodysplastic Syndrome, Chronic Thrombocytopenia
- Trial name
- EMATO0113 (NCT02057185)
- Testing
- Study questionnaire, SF-36 Questionnaire
- Where
- 6 sites in Italy
- Volunteers
- 141 people
- Sponsor
- Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child
Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant
This study will evaluate pediatric patients with malignant or non-malignant blood cell disorders who are having a blood stem cell transplant depleted of T cell receptor (TCR) alfa and beta cells that comes from a partially…
- Conditions
- Acute Lymphoblastic Leukemia, Leukemia, Acute Myeloid (AML), Child, Lymphoma, Non-Hodgkin, Myelodysplastic Syndromes
- Trial name
- NCT03301168
- Testing
- BPX-501 T cells, Rimiducid
- Where
- 10 sites in United States
- Volunteers
- 120 people
- Sponsor
- Bellicum Pharmaceuticals
Leukemia, Lymphoma
Antiviral Therapy Plus Either Peripheral Stem Cell or Umbilical Cord Blood Transplantation in Treating Patients Who Are HIV Positive and Have Hematologic Cancer
RATIONALE: Antiviral agents are drugs that act against viruses and may be an effective treatment for HIV. Peripheral stem cell transplantation or umbilical cord blood transplantation may be able to replace immune cells that were…
- Trial name
- NCT00003435
- Testing
- anti-thymocyte globulin, melphalan, antiviral therapy
- Where
- United States
- Sponsor
- Duke University
Hematologic Malignancies, Bone Marrow Transplant Rejection
Stem Cell Transplantation and T-Cell Add-Back to Treat Bone Marrow Malignancies
This study will evaluate the safety and effectiveness of stem cell transplantation in which the donor's T cells (a type of lymphocyte, or white blood cell) are removed and then added back.
- Trial name
- NCT00079391
- Testing
- allogeneic hematopoietic stem cell transplantation
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Leukemia, Lymphoma
Donor Stem Cell Transplant in Treating Patients With High-Risk Hematologic Cancer
RATIONALE: Giving low doses of chemotherapy before a donor stem cell transplant helps stop the growth of cancer cells. It may also stop the patient's immune system from rejecting the donor's stem cells.
- Conditions
- Leukemia, Lymphoma, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
- Trial name
- NCT00818961
- Testing
- alemtuzumab, graft-versus-tumor induction therapy, rituximab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northside Hospital, Inc.